Amgen Reports Aimovig ™ (Erenumab) Met All Primary And Secondary Endpoints In Unique Phase 3b Study In Episodic Migraine Patients Who Have Failed Multiple Prior Preventive Treatments

LIBERTY is the First Migraine Prevention Trial of its Kind Conducted Specifically in Patients Who Have Tried Multiple Therapies Without Success, and are in Need of Additional Treatment Options The Trial Met its Primary Endpoint of Percentage of Patients on Aimovig Achieving at Least a 50 Percent Reduction of Migraine Days Versus Placebo, and all Secondary Endpoints Results Add to the Consistent Efficacy, Safety and Tolerability Profile of Aimovig Across the Spectrum of Migraine, Even in More Difficult to Treat Patients THOUSAND OAKS, Calif., Jan. 22, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced positive results from the Phase 3b LIBERTY study assessing the efficacy and s...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news